Arteris (NASDAQ: AIP) CFO sells 5,836 shares via 10b5-1 plan

Rhea-AI Filing Summary

Arteris, Inc. reported that its VP and Chief Financial Officer, Nicholas B. Hawkins, sold 5,836 shares of common stock on January 7, 2026. The shares were sold under a pre-arranged Rule 10b5-1 trading plan that he adopted on June 4, 2025.

The sale was executed at a weighted average price of $17.272 per share, with individual trades occurring between $16.95 and $17.44. Following this transaction, Hawkins beneficially owns 82,267 shares of Arteris common stock, which includes 144 shares acquired on November 21, 2025 through the company’s Employee Stock Purchase Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hawkins Nicholas B.

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CA 95008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP and Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		S(1)		5,836	D	$17.272(2)	82,267(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on June 4, 2025.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.95 to $17.44 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Includes 144 of shares of common stock acquired on November 21, 2025 pursuant to the Issuer's Employee Stock Purchase Plan.

Remarks:

	/s/ Paul Alpern, as Attorney-in-Fact for Hawkins Nicholas B.	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Arteris (AIP) disclose?

Arteris disclosed that its VP and Chief Financial Officer, Nicholas B. Hawkins, sold 5,836 shares of the company’s common stock on January 7, 2026.

At what price did the Arteris (AIP) CFO sell his shares?

The shares were sold at a weighted average price of $17.272 per share, in multiple trades at prices ranging from $16.95 to $17.44.

Was the Arteris (AIP) CFO sale part of a 10b5-1 trading plan?

Yes. The filing states the sale was made under a Rule 10b5-1 trading plan that Nicholas B. Hawkins adopted on June 4, 2025.

How many Arteris (AIP) shares does the CFO own after this transaction?

After the sale, Nicholas B. Hawkins beneficially owns 82,267 shares of Arteris common stock.

Does the CFO’s remaining Arteris (AIP) stake include shares from the Employee Stock Purchase Plan?

Yes. The total of 82,267 shares includes 144 shares acquired on November 21, 2025 under Arteris’s Employee Stock Purchase Plan.

Who signed the Arteris (AIP) insider transaction filing?

The filing was signed by /s/ Paul Alpern, acting as attorney-in-fact for Nicholas B. Hawkins.